Evidence map›Paper›PMID 22615013›Full record

ArticleDigestive diseases and sciences2012

Proton pump inhibitors increase the incidence of bone fractures in hepatitis C patients.

Michael Mello, Rick A Weideman, Bertis B Little, Mark W Weideman, Byron Cryer, Geri R Brown

Abstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Proton-pump inhibitors and risk of fractures: an update meta-analysis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2016
    Pooled it
  2. Nonsteroidal anti-inflammatory drugs, gastroprotection, and benefit-risk.Pain practice : the official journal of World Institute of Pain · 2014
    Pooled it
  3. Open reduction internal fixation of rib fractures: a biomechanical comparison between the RibLoc U PlusEuropean journal of trauma and emergency surgery : official publication of the European Trauma Society · 2023
    Article
  4. Article
  5. Proton pump inhibitors and risk of bone fractures.Current treatment options in gastroenterology · 2014
    Article
  6. Canadian Association of Gastroenterology position statement: hip fracture and proton pump inhibitor therapy-a 2013 update.Canadian journal of gastroenterology = Journal canadien de gastroenterologie · 2013
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Michael MelloDepartment of Medical Service, Division of Digestive Diseases, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA. Michael.mello@phhs.org
Rick A Weideman
Bertis B Little
Mark W Weideman
Byron Cryer
Geri R Brown
Dallas VA Medical Center · USThe University of Texas Southwestern Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhile proton pump inhibitors (PPI) may increase the risk of bone fractures, the incidence of new bone fractures in a chronic hepatitis C virus (HCV) infected cohort, with or without PPI exposure, has not been explored.

methodsA retrospective cohort study of the incidence of bone fractures over 10 years in 9,437 HCV antibody positive patients in the Dallas VA Hepatitis C Registry was performed. The study endpoint was the incidence of verified new bone fractures per patient-years (pt-yrs) in PPI users compared to non-PPI users. PPI use was defined as those taking a PPI for ≥360 days. Pt-yrs of exposure for PPI users began on the first PPI prescription date, and pt-yrs of exposure for non-PPI users began with first date of any non-PPI prescription. For both HCV groups, the final date of patients' study duration was defined by end of PPI exposure, bone fracture occurrence, death or end of study evaluation period. Exclusion criteria included use of bone health modifying medications ≥30 days. Statistical differences in fracture incidence between groups were determined by multivariate regression analysis.

resultsAmong the total study population analyzed (n = 2,573), 109 bone fractures occurred. Unadjusted bone fracture incidences were 13.99/1,000 pt-yrs vs. 5.86/1,000 pt-yrs in PPI and non-PPI users, respectively. The adjusted hazard ratio for new bone fractures was 3.87 (95 % CI 2.46-6.08) (p < 0.001) in PPI users.

conclusionsIn patients with chronic HCV, use of PPI for >1 year increased the risk of new bone fractures by more than threefold.

Indexed as

AdultAgedAged, 80 and overCohort StudiesFractures, BoneHepatitis C AntibodiesHepatitis C, ChronicHumansMiddle AgedProton Pump InhibitorsRetrospective StudiesRisk FactorsTexasHepatitis C AntibodiesProton Pump Inhibitors

Identifiers

PMID22615013
OpenAlexW2021032344

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.